CAR-T Cell Therapy - Chimeric Antigen Receptor T-cell Immunotherapy

Advanced immunotherapy for multiple myeloma, lymphoma, and leukemia. ORR up to 96.4% with total cost $200,000-$250,000, far lower than Western countries. Enrollment in 2-4 weeks.

Chimeric Antigen Receptor T-cell immunotherapy treating blood cancers with world-class clinical outcomes.

  • Multiple Myeloma
  • High-grade Lymphoma
  • Acute Lymphoblastic Leukemia (ALL)
  • Other B-cell malignancies
  • ORR up to 96.4% for multiple myeloma
  • Cost advantage: $200K-$250K vs $500K+ in West
  • Minimal waiting: 2-4 weeks vs 6-12 months
  • Over 4,000 infusions completed
  • Flexible clinical trial access

Evaluation → Cell collection → CAR-T preparation → Infusion → Monitoring → Follow-up